NCT07002177 2026-01-07A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BCForward Pharmaceuticals Co., Ltd.Phase 1/2 Recruiting196 enrolled
NCT05258747 2024-10-03A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast CancerSandozPhase 1 Completed70 enrolled 13 charts